title: Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategies.
abstract: Fibrosis is a fundamental component of the adverse structural remodelling of myocardium found in hypertensive heart disease (HHD). A replacement fibrosis appears at sites of previous cardiomyocyte necrosis to preserve the structural integrity of the myocardium. Such scarring has adverse functional consequences. The extensive distribution of fibrosis involving the right and left heart suggests cardiomyocyte necrosis is widespread. Together, the loss of these contractile elements and fibrous tissue deposition in the form of stiff in-series and in-parallel elastic elements contribute to the progressive failure of this normally efficient muscular pump. Pathogenic mechanisms modulating fibrous tissue formation at sites of repair include auto/paracrine properties of locally generated angiotensin II and endothelin-1. This study focuses on the signal-transducer-effector pathway involved in cardiomyocyte necrosis and the crucial pathogenic role of intracellular calcium overloading, and the subsequent induction of oxidative stress originating within its mitochondria that dictates the opening of the mitochondrial permeability transition pore. The ensuing osmotic destruction of these organelles is followed by necrotic cell death. It is now further recognized that calcium overloading of cardiac myocytes and mitochondria functioning as pro-oxidant is pathophysiologically counterbalanced by an intrinsically coupled zinc entry, which serves as an antioxidant. The prospect of raising intracellular zinc by adjuvant nutriceutical supplementation can, therefore, be preferentially exploited to uncouple this intrinsically coupled calcium-zinc dyshomeostasis in favour of endogenous antioxidant defences. Novel cardioprotective strategies may thus be at hand and deserve to be explored further in the overall management of patients with HHD.
authors.affiliation: University of Tennessee Health Science Center, 956 Court Ave., Memphis, TN 38163, USA.
authors.forename: Atta U
authors.initials: AU
authors.lastname: Shahbaz
authors.forename: Yao
authors.initials: Y
authors.lastname: Sun
authors.forename: Syamal K
authors.initials: SK
authors.lastname: Bhattacharya
authors.forename: Robert A
authors.initials: RA
authors.lastname: Ahokas
authors.forename: Ivan C
authors.initials: IC
authors.lastname: Gerling
authors.forename: Jesse E
authors.initials: JE
authors.lastname: McGee
authors.forename: Karl T
authors.initials: KT
authors.lastname: Weber
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D044383:Black People; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D005355:Fibrosis; D006331:Heart Diseases / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012083:Renin / Q000097:blood
chemical_list: D000975:Antioxidants; D002316:Cardiotonic Agents; D012083:Renin
references.citation: Circulation. 2006 Jan 31;113(4):544-54
references.pmid: 16432057
references.citation: Food Chem Toxicol. 2000 Feb-Mar;38(2-3):237-53
references.pmid: 10717363
references.citation: J Hypertens. 1986 Apr;4(2):157-63
references.pmid: 3011889
references.citation: J Mol Cell Cardiol. 1977 Feb;9(2):151-9
references.pmid: 839549
references.citation: J Clin Invest. 1981 Sep;68(3):646-54
references.pmid: 7276164
references.citation: Hypertension. 2001 Jun;37(6):1444-9
references.pmid: 11408393
references.citation: Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H286-94
references.pmid: 16373592
references.citation: Circulation. 2004 Sep 28;110(13):1819-25
references.pmid: 15364804
references.citation: J Cardiovasc Pharmacol. 2009 May;53(5):414-23
references.pmid: 19333130
references.citation: J Pharmacol Exp Ther. 2007 May;321(2):517-25
references.pmid: 17322024
references.citation: Am J Med Sci. 2008 Apr;335(4):292-7
references.pmid: 18414068
references.citation: Circulation. 2005 Jan 4;111(1):51-7
references.pmid: 15611366
references.citation: Kidney Int. 1989 Sep;36(3):453-7
references.pmid: 2593489
references.citation: Auton Neurosci. 2003 Feb 28;104(1):47-57
references.pmid: 12559203
references.citation: Hypertension. 1995 Jun;25(6):1135-43
references.pmid: 7768553
references.citation: J Bone Miner Metab. 2000;18(3):109-25
references.pmid: 10783844
references.citation: J Cardiovasc Pharmacol. 2008 Apr;51(4):359-64
references.pmid: 18427278
references.citation: J Mol Cell Cardiol. 1997 Aug;29(8):2001-12
references.pmid: 9281434
references.citation: Am J Med Sci. 2006 Aug;332(2):73-78
references.pmid: 16909053
references.citation: J Clin Invest. 1985 Aug;76(2):470-3
references.pmid: 3839801
references.citation: Ann Intern Med. 1986 Nov;105(5):649-54
references.pmid: 3532893
references.citation: Hypertension. 2002 Oct;40(4):504-10
references.pmid: 12364354
references.citation: Cardiovasc Res. 1997 Jul;35(1):138-47
references.pmid: 9302358
references.citation: Circ Res. 2003 Nov 14;93(10):e124-35
references.pmid: 14576195
references.citation: Br Heart J. 1984 Jun;51(6):637-42
references.pmid: 6234010
references.citation: JAMA. 1963 Mar 9;183:871-8
references.pmid: 14022604
references.citation: Circulation. 2000 Apr 11;101(14):1722-8
references.pmid: 10758056
references.citation: Am J Med. 1987 Jan 26;82(1B):27-33
references.pmid: 3544831
references.citation: Verh Dtsch Ges Pathol. 1967;51:15-30
references.pmid: 4174681
references.citation: Circ Res. 1990 Dec;67(6):1355-64
references.pmid: 1700933
references.citation: J Cardiovasc Pharmacol. 2010 Mar;55(3):248-54
references.pmid: 20051880
references.citation: Am J Physiol. 1993 Jun;264(6 Pt 2):H1998-2006
references.pmid: 8322930
references.citation: Hypertension. 1991 Nov;18(5 Suppl):III143-9
references.pmid: 1937678
references.citation: Exp Neurol. 1987 Feb;95(2):265-76
references.pmid: 3803514
references.citation: Curr Med Chem. 2008;15(22):2192-222
references.pmid: 18781944
references.citation: Med Clin North Am. 2009 May;93(3):637-45
references.pmid: 19427496
references.citation: J Cardiovasc Pharmacol. 2008 Sep;52(3):245-52
references.pmid: 18806605
references.citation: Circulation. 2005 Feb 22;111(7):871-8
references.pmid: 15710759
references.citation: N Engl J Med. 1972 Mar 2;286(9):441-9
references.pmid: 4257928
references.citation: Eur Heart J. 1983 Dec;4 Suppl H:43-50
references.pmid: 6662132
references.citation: Am J Physiol Heart Circ Physiol. 2004 Nov;287(5):H2023-6
references.pmid: 15475529
references.citation: J Clin Endocrinol Metab. 1962 Dec;22:1187-92
references.pmid: 13964048
references.citation: Invest Clin. 1997 Nov;38 Suppl 2:27-40
references.pmid: 9471228
references.citation: Am J Hypertens. 1995 Sep;8(9):884-93
references.pmid: 8541003
references.citation: Hypertension. 2003 Jul;42(1):49-55
references.pmid: 12782645
references.citation: Biol Trace Elem Res. 2005 Nov;107(2):89-99
references.pmid: 16217134
references.citation: Clin Nephrol. 2002 Jan;57(1):51-5
references.pmid: 11837801
references.citation: N Engl J Med. 2001 Dec 6;345(23):1689-97
references.pmid: 11759649
references.citation: Hypertension. 1999 Apr;33(4):981-6
references.pmid: 10205234
references.citation: Am J Pathol. 2002 Nov;161(5):1773-81
references.pmid: 12414524
references.citation: J Clin Invest. 1942 Sep;21(5):601-11
references.pmid: 16694950
references.citation: Am J Physiol Heart Circ Physiol. 2010 Feb;298(2):H385-94
references.pmid: 19915175
references.citation: Am J Med Sci. 2008 Feb;335(2):105-10
references.pmid: 18277117
references.citation: J Clin Invest. 1970 Jul;49(7):1415-26
references.pmid: 4317384
references.citation: J Clin Invest. 1994 Jun;93(6):2578-83
references.pmid: 8200995
references.citation: Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2361-6
references.pmid: 17616752
references.citation: Muscle Nerve. 1982 Jan;5(1):73-8
references.pmid: 7057811